Unfortunately, no cogent tool based on PD-L1/PD-L2 tumor or TME expression has proven of sufficient clinical benefit, and documented responses to PD-L1-negative tumors indicate the lack of discriminative power for these pathological factors [83]. The gene discussed is CD274; the disease is neoplasm.